Drug Profile


Alternative Names: AZD-2281; KU-0059436; KU-59436; Lynparza

Latest Information Update: 29 Mar 2017

Price : $50

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer AstraZeneca; Cancer Research UK; M. D. Anderson Cancer Center; Massachusetts General Hospital; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University Health Network; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Breast cancer; Pancreatic cancer; Prostate cancer
  • Phase II Solid tumours
  • Phase I/II Fallopian tube cancer; Glioblastoma; Head and neck cancer; Peritoneal cancer; Small cell lung cancer
  • Phase 0 Endometrial cancer
  • No development reported Colorectal cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 14 Mar 2017 Efficacy and adverse evens data from the phase III SOLO-2 trial in Ovarian cancer released by AstraZeneca
  • 08 Mar 2017 AstraZeneca initiates an expanded access program for Ovarian cancer (Maintenance therapy) before March 2017(NCT03079687)
  • 27 Feb 2017 AstraZeneca initiates an expanded access program for Ovarian cancer (Monotherapy, Second-line therapy or greater) before February 2017 (NCT03063710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top